Woman and child walking outside their home

For treatment of PI in adults and pediatric patients ≥2 years

Ready. Steady. Go.

WITH HIZENTRA

Steady Ig Levels1,2

Review data: Hizentra maintains consistent steady-state Ig levels vs IVIg

Continuous Protection3*

Efficacy demonstrated for Hizentra across 7 major studies

Innovative Personalization

Hizentra is the first and only SCIg with prefilled syringes and multiple dosing schedules

*A prospective, open-label, single-arm, Phase 3 study evaluated the safety and efficacy of weekly subcutaneous Hizentra in patients with PI previously on IVIg every 3 or 4 weeks (MITT, n=38). The primary end point, annual rate of SBIs per patient, was 0 (upper 99% CI, 0.132). In a pooled analysis of 7 studies, 125 unique patients received 15,013 weekly infusions during a total observation period of 250.9 patient-years.2,3

Hizentra is a 20% SCIg infusion indicated for the treatment of PI

Delivering RESULTS YOU CAN TRUST

Badge with number

#1 Ig prescribed
for PI4

16+ years of Hizentra subcutaneous immune globulin clinical experience badge

Only 20% SCIg with proven experience since 2010

19 million badge

More than 19 million doses delivered worldwide4†

†Estimated doses based on grams of Hizentra sold worldwide from 2010 through June 2026.

Healthcare provider showing a patient how to use a Hizentra prefilled syringe for subcutaneous Ig infusion

Prefer prefilled syringes?

Patients can work with their care team and specialty pharmacies to adjust infusion volume, frequency, duration, and sites. Prefilled syringes may offer additional flexibility.

Explore Dosing OptionsPrescription pad illustration with SCIg checked and Hizentra written by name for dispense as written

Prescribe Hizentra by name

Access enrollment forms—and remember to include “Dispense as written” on referral forms.

Get Enrollment Forms

Abbreviations: Ig, immunoglobulin; IVIg, intravenous immunoglobulin; MITT, modified intention-to-treat; PI, primary immunodeficiency; SBI, serious bacterial infection; SCIg, subcutaneous immunoglobulin.

References: 1. Wasserman RL, Melamed I, Nelson RP Jr, et al. Clin Pharmacokinet. 2011;50(6):405-414. doi:10.2165/11587030-000000000-00000 2. Hagan JB, Fasano MB, Spector S, et al. J Clin Immunol. 2010;30(5):734-745. doi:10.1007/s10875-010-9423-4 3. Jolles S, Rojavin MA, Lawo JP, et al. J Clin Immunol. 2018;38(8):864-875. doi:10.1007/s10875-018-0560-5 4. Data on File. Available from CSL Behring as DOF HIZ-005.

IMPORTANT SAFETY INFORMATION

WARNING: Thrombosis may occur with immune globulin products, including Hizentra. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.

For patients at risk of thrombosis, administer Hizentra at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin (Ig) or components of Hizentra (eg, polysorbate 80), as well as in patients with immunoglobulin A deficiency with antibodies against IgA and a history of hypersensitivity. Because Hizentra contains L-proline as stabilizer, use in patients with hyperprolinemia is contraindicated.

IgA-deficient patients with anti-IgA antibodies are at greater risk of severe hypersensitivity and anaphylactic reactions. Thrombosis may occur following treatment with Ig products, including Hizentra.

Monitor patients for aseptic meningitis syndrome (AMS), which may occur following treatment with Ig products, including Hizentra. In patients at risk of acute renal failure, monitor renal function, including blood urea nitrogen, serum creatinine and urine output. In addition, monitor patients for clinical signs of hemolysis or pulmonary adverse reactions (eg, transfusion-related acute lung injury [TRALI]).

Hizentra is derived from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most common adverse reactions (observed in ≥5% of study subjects) were local infusion-site reactions, as well as headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, upper respiratory tract infection, rash, pruritus, vomiting, upper abdominal pain, migraine, arthralgia, pain, fall, and nasopharyngitis.

The passive transfer of antibodies can interfere with response to live virus vaccines and lead to misinterpretation of serologic test results.

Indications

Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is indicated for:

  • Treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years and older.
  • Maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.
    • Limitation of Use: Maintenance therapy in CIDP has been systematically studied for 6 months and for a further 12 months in a follow-up study. Continued maintenance beyond these periods should be individualized based on patient response and need for continued therapy.

For subcutaneous infusion only.

Please see full Prescribing Information for Hizentra including boxed warning.

To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.

Hizentra® is a registered trademark of CSL Behring AG.

Hizentra Connect℠ is a service mark of CSL Behring LLC.

CONTINUOUS PROTECTION1-4*†

Hizentra provides Ig stability from dose to dose, delivering reliable protection.1,2,4,5

SELECT AN INDICATION:

PI

Primary
immunodeficiency

CIDP

Chronic inflammatory demyelinating polyneuropathy

*A prospective, open-label, single-arm, Phase 3 study evaluated the safety and efficacy of weekly subcutaneous Hizentra in patients with PI previously on monthly IVIg (n=38). The primary end point, annual rate of SBIs per patient, was 0 (upper 99% CI, 0.132).1

†A randomized, multicenter, double-blind, placebo-controlled, parallel-group, 24-week, Phase 3 study and a 48-week, open-label, prospective extension study evaluated the safety and efficacy of Hizentra vs placebo for the maintenance treatment of CIDP. The primary end point, relapse or withdrawal, was significantly reduced vs placebo.

Abbreviations: Ig, immunoglobulin; IVIg, intravenous immunoglobulin; SBI, serious bacterial infection.

References: 1. Hagan JB, Fasano MB, Spector S, et al. J Clin Immunol. 2010;30(5):734-745. doi:10.1007/s10875-010-9423-4 2. Tortorici MA, Yuraszeck T, Cornblath D, et al. CPT Pharmacometrics Syst Pharmacol. 2021;10(8):839-850. doi:10.1002/ psp4.12647 3. van Schaik IN, Mielke O, Bril V, et al. Neurol Neuroimmunol Neuroinflamm. 2019;6(5):e590. doi:10.1212/NXI.0000000000000590 4. van Schaik IN, Bril V, van Geloven N, et al. Lancet Neurol. 2018;17(1):35-46. doi:10.1016/S1474-4422(17)30378-2 5. Wasserman RL, Melamed I, Nelson RP Jr, et al. Clin Pharmacokinet. 2011;50(6):405-414. doi:10.2165/11587030-000000000-00000

You are now leaving the current website.

The site you are accessing is maintained by a third party over whom CSL Behring has no control. CSL Behring does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site. CSL Behring is not responsible for third-party content or the consequences of your use thereof.

Do you want to continue?